Loading...
Loading...
SNPX| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 1.7K |
| Gross Profit | -1.7K |
| Operating Expense | 1,829.7K |
| Operating I/L | 4,094.0K |
| Other Income/Expense | -2,264.2K |
| Interest Income | 427.2K |
| Pretax | -4,094.0K |
| Income Tax Expense | -6,116.6K |
| Net Income/Loss | -4,094.0K |
Synaptogenix, Inc. is a biopharmaceutical company focused on developing a product platform based on the drug candidate Bryostatin-1 for the treatment of Alzheimer's disease. The company also explores therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. generates revenue through its product candidates in pre-clinical and clinical development, as well as through licensing agreements with prominent institutions such as Stanford University and the Icahn School of Medicine at Mount Sinai.
